T-Cell Lymphomas - Pipeline Review, H2 2014

Global Markets Direct
October 31, 2014
143 Pages - SKU: GMD5380169
T-Cell Lymphomas - Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘T-Cell Lymphomas - Pipeline Review, H2 2014’, provides an overview of the T-Cell Lymphomas’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for T-Cell Lymphomas, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for T-Cell Lymphomas and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope
  • The report provides a snapshot of the global therapeutic landscape of T-Cell Lymphomas
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
  • The report reviews key players involved in the therapeutics development for T-Cell Lymphomas and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects
  • A review of the T-Cell Lymphomas products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the T-Cell Lymphomas pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products
Reasons to buy
  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for T-Cell Lymphomas
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding T-Cell Lymphomas pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline



More Oncology/Hematology reports by Global Markets Direct

Adenocarcinoma of the Gastroesophageal Junction - Pipeline Review, H2 2014 by Global Markets Direct
Adenocarcinoma of the Gastroesophageal Junction - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Adenocarcinoma Of The Gastroesophageal Junction - Pipeline Review, H2 2014’, provides an overview ...
Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2014 by Global Markets Direct
Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Chemotherapy Induced Nausea and Vomiting - Pipeline Review, H2 2014’, provides an overview ...
Thyroid Cancer - Pipeline Review, H2 2014 by Global Markets Direct
Thyroid Cancer - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Thyroid Cancer - Pipeline Review, H2 2014’, provides an overview of the Thyroid Cancer’s therapeutic pipeline.This ...
Esophageal Cancer - Pipeline Review, H2 2014 by Global Markets Direct
Esophageal Cancer - Pipeline Review, H2 2014SummaryGlobal Markets Direct’s, ‘Esophageal Cancer - Pipeline Review, H2 2014’, provides an overview of the Esophageal Cancer’s therapeutic pipeline.This ...
See all reports like this >>

 

SELECT A LICENSE

    Online Download  USD 2,000  
    Site License  USD 4,000  
    Global Site License  USD 6,000  
 
US: 800.298.5699
Int'l: +1.240.747.3093
 

Share this report


    Other tasks

     
     
    Join Alert Me now!
    Receive bi-weekly email alerts on new market research

    Sign up today!